“…Similar to RDoC, PRISM study participants with a range of neuropsychiatric symptoms will be assessed using multiple methods in an attempt to parse current heterogeneous syndromes into homogeneous clusters. Additional European agency‐funded efforts consistent with an RDoC focus (Bong, Choi, Kim, Lee, & Kim, 2020; Destoop, Morrens, Coppens, & Dom, 2019; Hengartner & Lehmann, 2017; Hirjak, Wolf, & Northoff, 2019; Holroyd & Umemoto, 2016; Kleinman et al., 2015; Luyten & Fonagy, 2018) include efforts focused on intervention development (Pasion, Martins, & Barbosa, 2019), and drug discovery (Andersen et al., 2014; Fibiger, 2012; O'Tuathaigh, Moran, Zhen, & Waddington, 2017; Tricklebank, Robbins, Simmons, & Wong, 2021), and autism biomarker identification (Loth et al., 2017).…”